About Symbio Generrics
Symbio Generrics is a Healthcare company based in Mumbai (India) founded in 2010 by Salim Sadiq Shaikh and Abhijit Govindrao Kale. CDMO manufacturer of APIs and Intermediates. Symbio Generrics has raised $12.86 million across 2 funding rounds from investors including Ascent Capital, Aahi Family Trust and Vivek Gupta. The company has 226 employees. Symbio Generrics was last valued at $24.31 million in March 2022. Its chief executive, as recorded, is Akash Puranik. Its Indian entity Symbio Generrics India Private Limited reported revenue of ₹435 Cr. Symbio Generrics offers products and services including Active Pharmaceutical Ingredients and Intermediates. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.
Company details
Symbio Generrics was established in 2010 in Mumbai, India, and operates as a contract development and manufacturing organization in the pharmaceutical sector. Active pharmaceutical ingredients and intermediates are produced for clients through specialized processes. The company is led by co-founders Salim Sadiq Shaikh and Abhijit Govindrao Kale, with Akash Puranik serving as CEO and managing director. Operations are centered on regulatory-compliant manufacturing.
- Headquarters Mumbai, India
- Employees 226
- Founders Salim Sadiq Shaikh, Abhijit Govindrao Kale
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website symbiogenerics.com
- Social LinkedIn
- Legal Name Symbio Generrics India Private Limited
- Date of Incorporation 30 May, 2011
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹435 Cr
FY 2025 · -11% YoY
- Net Profit₹4.57 Cr
FY 2025 · 1% margin
- EBITDA₹29.66 Cr
FY 2025 · 7% margin
- Total Equity Funding$12.86M (USD)
in 2 rounds
- Latest Funding Round$12.86M (USD), Private Equity Round
Mar 2022
- InvestorsAscent Capital
& 9 more
- Employee Count226
Associated legal entities of Symbio Generrics
Symbio Generrics operates through Symbio Generrics India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Symbio Generrics India Private Limited CIN U74990KA2011PTC184231 | Active | 30 May 2011 | Bangalore, Karnataka | ₹435 Cr | 161 | 5 | View details |
Products & Services of Symbio Generrics
Symbio Generrics offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and Intermediates.
Active Pharmaceutical Ingredients are manufactured and marketed by Symbio Generrics for various therapeutic areas
Intermediates are produced by Symbio Generrics for the development and manufacturing of APIs
Funding Insights of Symbio Generrics
Symbio Generrics has successfully raised a total of $12.86M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $12.86 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.86M
- Total Rounds 2
- Last Round Private Equity Round — $12.86M
- First Round $68,896
(Mar 2022)
- Investors Count 10
All 2 funding rounds of Symbio Generrics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $12.86M | Private Equity Round | $24.31M | Ascent Capital | – |
| Mar 2022 | $68,896 | Unspecified | $933,499 | Aahi Family Trust |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2022 | $24.31M | •••••••• |
Last known valuation $24.31M (Mar 2022). 10 investors in total: 2 institutional and 8 angel.
Investors in Symbio Generrics
Symbio Generrics has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Ascent Capital, Aahi Family Trust and Vivek Gupta.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AscentCapital is engaged in potato farming, grain marketing, and equipment services in Maine. | 2000 | ascentcapital.in | Bengaluru, India | |
VG Vivek Gupta | Angel investor, tech entrepreneur, ex-Microsoft, focused on Indian startups | unknown_907fdaff77e34423a | ||
CS Chandan Shetty | unknown_1cb41dca98ec441a8 | |||
JR Jayashree Rao | unknown_79dc51d60caa4d5fb | |||
SG Saurabh Gupta | unknown_7ec15cb953244e5c8 | |||
NG Nitin Gupta | unknown_fc897bcd624c4a05a | |||
RR Rashmi Rao | unknown_cde2d71552d14eb59 | |||
PR Pudhucode Radhakrishna Kanan | unknown_fc76b609ec2c458f9 | |||
PK Pradeep Kumar | unknown_9020ed8dc668454ab |
Investor details for Symbio Generrics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Symbio Generrics India Private Limited (Symbio Generrics)
Symbio Generrics India Private Limited is the primary company behind Symbio Generrics. The board of Symbio Generrics India Private Limited currently have 4 directors; the longest-serving is Salim Sadiq Shaikh, appointed in 2011. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Salim Sadiq Shaikh DIN 03398407 | Whole-time director | 30 May 2011 | 15 yrs 5 mo | Symbio Generrics India Private Limited |
| Akash Suresh Puranik DIN 06775891 | Managing Director | 30 Sep 2017 | 9 yrs 1 mo | Symbio Generrics India Private Limited |
| Deepak Komaregowda DIN 03298261 | Nominee Director | 30 Mar 2022 | 4 yrs 7 mo | Symbio Generrics India Private Limited |
| Kannan Natraj Sharma DIN 00408118 | Director | 19 Sep 2022 | 4 yrs 1 mo | Symbio Generrics India Private Limited |
People of Symbio Generrics
3 people are tracked at Symbio Generrics (3 in leadership); the tracked headcount is 226.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder | Leadership | |
| CEO & MD | Leadership |
Complete people profiles for Symbio Generrics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Symbio Generrics
Figures of Symbio Generrics India Private Limited, the primary company behind Symbio Generrics, for FY 2025. Revenue was ₹435 Cr (-11% year on year). Net profit was ₹4.57 Cr (1% margin). EBITDA was ₹29.66 Cr (7% margin). Revenue has grown at a compounded annual rate of 0% over three years and 0% over five years.
- ₹435 CrRevenue · FY 2025 · -11% YoY
- ₹4.57 CrNet profit · 1% margin
- ₹29.66 CrEBITDA · 7% margin
- ₹3.01 CrPaid-up capital
- 161Employees (provident fund records)
- 0%Revenue CAGR, 3 years
- 0%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Symbio Generrics India Private Limited are on its company page.
Detailed financial statements for Symbio Generrics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Symbio Generrics
4 dated milestones of Symbio Generrics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Symbio Generrics is founded.
- Funding First funding round of $69K.
- Funding Latest funding round, Private Equity Round, of $12.9M.
- Milestone Reaches Minicorn status.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Symbio Generrics (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Symbio Generrics
Symbio Generrics was founded in 2010 and raised its 1st funding round 12 years after it was founded.
Symbio Generrics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Akash Puranik is the CEO of Symbio Generrics, as recorded in our data.
Symbio Generrics is a funded company, having raised a total of $12.86M across 2 funding rounds to date. The company's 1st funding round was a Unspecified of $68.9K, raised on Mar 2022.
Symbio Generrics has 226 employees.
The primary company behind Symbio Generrics, Symbio Generrics India Private Limited, reported revenue of ₹435 Cr for FY 2025, down 11% year on year.
Symbio Generrics was established in 2010 in Mumbai, India, and operates as a contract development and manufacturing organization in the pharmaceutical sector. Active pharmaceutical ingredients and intermediates are produced for clients through specialized processes. The company is led by co-founders Salim Sadiq Shaikh and Abhijit Govindrao Kale, with Akash Puranik serving as CEO and managing director. Operations are centered on regulatory-compliant manufacturing.
Symbio Generrics offers Active Pharmaceutical Ingredients and Intermediates.
Symbio Generrics has 10 investors. Key investors include Ascent Capital, Aahi Family Trust, Vivek Gupta, Chandan Shetty, and Jayashree Rao.
The valuation of Symbio Generrics is $24.31M as of Mar 2022.
Symbio Generrics operates through Symbio Generrics India Private Limited.
The legal entities of Symbio Generrics currently have 4 directors, including Akash Suresh Puranik, Kannan Natraj Sharma, Salim Sadiq Shaikh and others.